HomeCompareSHAP vs JNJ

SHAP vs JNJ: Dividend Comparison 2026

SHAP yields 18.33% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHAP wins by $45.9K in total portfolio value
10 years
SHAP
SHAP
● Live price
18.33%
Share price
$10.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.9K
Annual income
$5,616.31
Full SHAP calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SHAP vs JNJ

📍 SHAP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHAPJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHAP + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHAP pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHAP
Annual income on $10K today (after 15% tax)
$1,558.20/yr
After 10yr DRIP, annual income (after tax)
$4,773.86/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, SHAP beats the other by $4,070.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHAP + JNJ for your $10,000?

SHAP: 50%JNJ: 50%
100% JNJ50/50100% SHAP
Portfolio after 10yr
$43.0K
Annual income
$3,222.04/yr
Blended yield
7.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SHAP
No analyst data
Altman Z
5.9
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHAP buys
0
JNJ buys
0
No recent congressional trades found for SHAP or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHAPJNJ
Forward yield18.33%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$65.9K$20.0K
Annual income after 10y$5,616.31$827.78
Total dividends collected$35.8K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHAP vs JNJ ($10,000, DRIP)

YearSHAP PortfolioSHAP Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,533$1,833.18$10,676$355.77+$1.9KSHAP
2$15,558$2,147.25$11,407$389.39+$4.2KSHAP
3$19,138$2,491.06$12,198$426.53+$6.9KSHAP
4$23,341$2,863.83$13,056$467.62+$10.3KSHAP
5$28,240$3,264.34$13,987$513.12+$14.3KSHAP
6$33,907$3,691.00$14,998$563.56+$18.9KSHAP
7$40,423$4,141.87$16,098$619.52+$24.3KSHAP
8$47,867$4,614.71$17,295$681.69+$30.6KSHAP
9$56,325$5,107.07$18,599$750.82+$37.7KSHAP
10$65,884$5,616.31$20,022$827.78+$45.9KSHAP

SHAP vs JNJ: Complete Analysis 2026

SHAPStock

Spree Acquisition Corp. 1 Limited does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus its search on technology-based mobility businesses. The company was incorporated in 2021 and is based in Tel Aviv, Israel.

Full SHAP Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SHAP vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHAP vs SCHDSHAP vs JEPISHAP vs OSHAP vs KOSHAP vs MAINSHAP vs ABBVSHAP vs MRKSHAP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.